Our Science
Breakthrough Science to Increase Healthy Lifespan
Prevalence of T2DM is expected to grow to 330 million cases globally by 2022 according to research firm Globaldata. Projections indicate that by 2030 global healthcare expenditures will exceed 490 Billion $
Diabetes Is Becoming A Global Epidemic
Pramana has the ability to advance its lead product in T2DM and address additional potential breakthrough therapeutics for metabolic disorders, such as Nash, Obesity Cardiovascular, Neurodegenerative diseases and Cancer.
Diabetes is one of the most common non-communicable diseases worldwide and is an escalating global public health problem. T2DM constitutes approximately 90% of all diabetes cases around the world.
T2DM is associated with several comorbidities, such as chronic kidney disease, cardiovascular disease, hypertension, fatty liver disease/nash, and dyslipidemia, which can worsen the quality of life of the patient, and can lead to poor therapeutic outcomes.
Aging and Comorbidities
Nearly 92% of older adults have at least one chronic condition. and 77% have at least two comorbidities.
Prescriptions taken each year
Prescriptions taken each year
Patients 65 to 69 years old take nearly 14 prescriptions, ages 80 to 84 take nearly 18 prescriptions per year.
Diseases considered to be global epidemics
Cardiovascular, obesity, diabetes, cancer, and respiratory diseases are global epidemics.
Aging and Comorbidities
Nearly 92% of older adults have at least one chronic condition. and 77% have at least two comorbidities.
The U.S. Medicare Budget
Alzheimer's disease, diabetes, heart disease and cancer are responsible for 80% of the U.S. Medicare budget.
The global cost of age-related diseases
Alzheimer's disease, diabetes, heart disease and cancer are estimated to cost over $30 trillion over the next 20 years.
